関連する実験動画
Updated: Jun 23, 2026

09:36
Changes in Mammary Gland Morphology and Breast Cancer Risk in Rats
Published on: October 17, 2010
乳がんリスクに対する産前影響の証拠
A Ekbom1, D Trichopoulos, H O Adami
1Cancer Epidemiology Unit, Uppsala University Hospital, Sweden.
Lancet (London, England)
|October 24, 1992
まとめ
妊娠ホルモンの産前暴露は,乳がんのリスクに影響を与える可能性があります. 妊娠前出血栓症 (妊娠合併症) などの症状は,より低いリスクと関連しており,胎児の大きさは,より高いリスクへの非有意な傾向を示しました.
科学分野:
- 生殖内分泌学 生殖内分泌学
- 腫瘍学 腫瘍学
- エピデミオロジー エピデミオロジー
背景:
- 妊娠中の内生性エストロゲンへの子宮内暴露は,乳がんの病因学に作用すると仮定されています.
- 妊娠中のエストロゲン濃度の指標には,プレエクラムプシア/エクラムプシア (陰性関連) と胎児のサイズ (陽性関連) が含まれる.
研究 の 目的:
- 乳がんリスクと妊娠中のエストロゲン濃度の指標との関連を調査する.
- 乳がん発生における産前要因の役割を評価する.
主な方法:
- ウプサラ大学病院 (1874年−1954年) の標準記録を用いて,ネストされた症例対照研究が行われました.
- 乳がんの症例は,スウェーデンのがん登録 (1958年-1990年) を通じて特定されました.
- 条件付きロジスティック回帰分析は,458例と1197匹の対照群で実施されました.
主要な成果:
- 前出血栓症/出血栓症は,乳がんリスクと有意な逆相関を示した (比率 = 0.24,p = 0.01).
- 出生体重,出生長,胎盤体重の増加は,乳がん発生率のポジティブだが,有意ではない傾向を示した.
結論:
- 妊娠前の要因は,乳がん発生において重要な役割を果たします.
- 妊娠中のエストロゲン濃度が寄与する要因かもしれないが,他の産前または産周の影響は排除できない.
関連する概念動画
mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
Cancer Prevention
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Cancer Prevention
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...

